A detailed history of Concorde Asset Management, LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Concorde Asset Management, LLC holds 3,103 shares of ABBV stock, worth $544,204. This represents 0.35% of its overall portfolio holdings.

Number of Shares
3,103
Previous 3,151 1.52%
Holding current value
$544,204
Previous $540,000 13.33%
% of portfolio
0.35%
Previous 0.34%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$163.84 - $199.33 $7,864 - $9,567
-48 Reduced 1.52%
3,103 $612,000
Q2 2024

Aug 12, 2024

BUY
$154.79 - $180.76 $12,537 - $14,641
81 Added 2.64%
3,151 $540,000
Q1 2024

May 15, 2024

BUY
$159.82 - $182.1 $34,201 - $38,969
214 Added 7.49%
3,070 $559,000
Q3 2023

Nov 09, 2023

SELL
$133.59 - $154.65 $2.74 Million - $3.17 Million
-20,503 Reduced 87.77%
2,856 $425,000
Q2 2023

Jul 25, 2023

SELL
$132.51 - $164.9 $837,065 - $1.04 Million
-6,317 Reduced 21.29%
23,359 $3.15 Million
Q1 2023

May 09, 2023

BUY
$144.61 - $166.54 $4 Million - $4.61 Million
27,677 Added 1384.54%
29,676 $4.73 Million
Q4 2022

Feb 02, 2023

BUY
$138.31 - $165.87 $5,809 - $6,966
42 Added 2.15%
1,999 $323,000
Q3 2022

Oct 31, 2022

BUY
$134.21 - $153.93 $262,648 - $301,241
1,957 New
1,957 $238,000
Q2 2022

Aug 05, 2022

SELL
$137.62 - $174.96 $293,405 - $373,014
-2,132 Closed
0 $0
Q1 2022

Apr 22, 2022

BUY
$131.98 - $163.75 $76,284 - $94,647
578 Added 37.19%
2,132 $317,000
Q4 2021

Feb 02, 2022

SELL
$107.43 - $135.93 $118,602 - $150,066
-1,104 Reduced 41.53%
1,554 $214,000
Q3 2021

Oct 21, 2021

BUY
$106.4 - $120.78 $67,989 - $77,178
639 Added 31.65%
2,658 $295,000
Q2 2021

Jul 20, 2021

SELL
$105.21 - $117.21 $855,462 - $953,034
-8,131 Reduced 80.11%
2,019 $230,000
Q1 2021

Apr 27, 2021

BUY
$102.3 - $112.62 $1.04 Million - $1.14 Million
10,150 New
10,150 $1.11 Million
Q3 2020

Oct 23, 2020

SELL
$85.91 - $100.83 $187,541 - $220,111
-2,183 Closed
0 $0
Q2 2020

Jul 20, 2020

BUY
$73.37 - $98.18 $160,166 - $214,326
2,183 New
2,183 $209,000
Q1 2020

Apr 22, 2020

SELL
$64.5 - $97.79 $183,696 - $278,505
-2,848 Closed
0 $0
Q4 2019

Jan 30, 2020

SELL
$72.13 - $90.25 $13,127 - $16,425
-182 Reduced 6.01%
2,848 $250,000
Q3 2019

Oct 28, 2019

SELL
$62.98 - $75.72 $45,408 - $54,594
-721 Reduced 19.22%
3,030 $239,000
Q2 2019

Aug 08, 2019

BUY
$65.7 - $83.98 $3,547 - $4,534
54 Added 1.46%
3,751 $293,000
Q1 2019

May 01, 2019

SELL
$77.14 - $90.79 $14,888 - $17,522
-193 Reduced 4.96%
3,697 $296,000
Q4 2018

Jan 25, 2019

BUY
$77.85 - $96.01 $25,924 - $31,971
333 Added 9.36%
3,890 $315,000
Q3 2018

Oct 30, 2018

BUY
$88.91 - $98.84 $70,683 - $78,577
795 Added 28.78%
3,557 $288,000
Q2 2018

Jul 17, 2018

SELL
$89.78 - $106.23 $14,275 - $16,890
-159 Reduced 5.44%
2,762 $203,000
Q1 2018

Apr 24, 2018

SELL
$92.01 - $123.21 $15,641 - $20,945
-170 Reduced 5.5%
2,921 $212,000
Q4 2017

Jan 23, 2018

BUY
$89.56 - $98.21 $447 - $491
5 Added 0.16%
3,091 $223,000
Q3 2017

Oct 31, 2017

BUY
$69.85 - $89.22 $215,557 - $275,332
3,086
3,086 $244,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $310B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Concorde Asset Management, LLC Portfolio

Follow Concorde Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Concorde Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Concorde Asset Management, LLC with notifications on news.